中文
Announcement
More
Progress in Chemistry 2013, Vol. 25 Issue (09): 1588-1593 DOI: 10.7536/PC130714 Previous Articles   Next Articles

Research Progress of Anti-Cancer Vaccine

Chen Jibing, Yuan Yuanying, Xu Kecheng*   

  1. Fuda Hospital, School of Medicine, Jinan University, Guangzhou 510665, China
  • Received: Revised: Online: Published:
Richhtml ( 3 ) PDF ( 1996 ) Cited
Export

EndNote

Ris

BibTeX

Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable is the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.

Contents
1 Introduction
2 Cancer vaccines are finally showing early signals of activity
3 An efficacious cell-based vaccine for prostate cancer
4 Combination immunotherapy
5 Recalling the use of vaccines
6 Perspective

CLC Number: 

[1] Dougan M, Dranoff G. Annu. Rev. Immunol., 2009, 27: 83—117
[2] Hall S S. A Commotion in the Blood: Life, Death, and the Immune System. New York: Henry Holt and Company, 1997
[3] Sylvester R J. International Journal of Urology, 2011, 18: 113—120
[4] Palucka K, Banchereau J, Mellman I. Immunity, 2010, 33: 464—478
[5] Boon T, Coulie P G, Van den Eynde B J, van der Bruggen P. Annu. Rev. Immunol., 2006, 24: 175—208
[6] Zhang L, Conejo-Garcia J R, Katsaros D, Gimotty P A, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman M N, Rubin S C, Coukos G. N. Engl. J. Med., 2003, 348: 203—213
[7] Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P H, Trajanoski Z, Fridman W H, Pages F. Science, 2006, 313: 1960—1964
[8] Rosenberg S A, Yang J C, Restifo N P. Nat. Med., 2004, 10: 909—915
[9] Schwartzentruber D J, Lawson D H, Richards J M, Conry R M, Miller D M, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra K L, White R L, Gonzalez R, Kuzel T M, Curti B, Leming P D, Whitman E D, Balkissoon J, Reintgen D S, Kaufman H, Marincola F M, Merino M J, Rosenberg S A, Choyke P, Vena D, Hwu P. N. Engl. J. Med., 2011, 364: 2119—2127
[10] Kenter G G, Welters M J, Valentijn A R, Lowik M J, Berends-van der Meer D M, Vloon A P, Essahsah F, Fathers L M, Offringa R, Drijfhout J W, Wafelman A R, Oostendorp J, Fleuren G J, van der Burg S H, Melief C J. N. Engl. J. Med., 2009, 361: 1838—1847
[11] Leffers N, Lambeck A J, Gooden M J, Hoogeboom B N, Wolf R, Hamming I E, Hepkema B G, Willemse P H, Molmans B H, Hollema H, Drijfhout J W, Sluiter W J, Valentijn A R, Fathers L M, Oostendorp J, van der Zee A G, Melief C J, van der Burg S H, Daemen T, Nijman H W. Int. J. Cancer, 2009, 125: 2104—2113
[12] Vansteenkiste J, Zielinksi M, Linder A, Dahabre J, Esteban E, Malinowski W, Jassem J, Passlick B, Lehmann F, Brichard V G. J. Thorac. Oncol., 2007, 2(8): S334—S335
[13] Freedman A, Neelapu S S, Nichols C, Robertson M J, Djulbegovic B, Winter J N, Bender J F, Gold D P, Ghalie R G, Stewart M E, Esquibel V, Hamlin P. J. Clin. Oncol., 2009, 27: 3036—3043
[14] Kantoff P W, Schuetz T J, Blumenstein B A, Glode L M, Bilhartz D L, Wyand M, Manson K, Panicali D L, Laus R, Schlom J, Dahut W L, Arlen P M, Gulley J L, Godfrey W R. J. Clin. Oncol., 2010, 28: 1099—1105
[15] Neller M A, Lopez J A, Schmidt C W. Seminars in Immunology, 2008, 20: 286—295
[16] Copier J, Dalgleish A. Current Opinion in Molecular Therapeutics, 2010, 12: 14—20
[17] Schuler G. Eur. J. Immunol., 2010, 40: 2123—2130
[18] Cheever M A, Schlom J, Weiner L M, Lyerly H K, Disis M L, Greenwood A, Grad O, Nelson W G. Clin. Cancer Res., 2008, 14: 5692—5699
[19] Rammensee H G, Weinschenk T, Gouttefangeas C, Stevanovic S. Immunol. Rev., 2002, 188: 164—176
[20] Small E J, Fratesi P, Reese D M, Strang G, Laus R, Peshwa M V, Valone F H. J. Clin. Oncol., 2000, 18: 3894—3903
[21] Kantoff P W, Higano C S, Shore N D, Berger E R, Small E J, Penson D F, Redfern C H, Ferrari A C, Dreicer R, Sims R B, Xu Y, Frohlich M W, Schellhammer P F. N. Engl. J. Med., 2010, 363: 411—422
[22] Wolchok J D, Hoos A, O'Day S, Weber J S, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi F S. Clin. Cancer Res., 2009, 15: 7412—7420
[23] Leach D R, Krummel M F, Allison J P. Science, 1996, 271: 1734—1736
[24] Hodi F S, Butler M, Oble D A, Seiden M V, Haluska F G, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch M T, Ramaiya N, Chen T C, Neuberg D, Allison J P, Mihm M C, Dranoff G. Proc. Natl. Acad. Sci. U. S. A., 2008, 105: 3005—3010
[25] Chapman P B, Hauschild A, Robert C, Haanen J B, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day S J, Sosman J A, Kirkwood J M, Eggermont A M, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee R J, Flaherty K T, McArthur G A. N. Engl. J. Med., 2011, 364: 2507—2516
[26] Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zawel L, Dranoff G. J. Exp. Med., 2010, 207: 2195—2206
[27] Ferrer I R, Wagener M E, Robertson J M, Turner A P, Araki K, Ahmed R, Kirk A D, Larsen C P, Ford M L. J. Immunol., 2010, 185: 2004—2008
[28] Machiels J P, Reilly R T, Emens L A, Ercolini A M, Lei R Y, Weintraub D, Okoye F I, Jaffee E M. Cancer Res., 2001, 61: 3689—3697
[29] Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June C H, Powell D J Jr, Coukos G. J. Transl. Med., 2011, 9: art. no. 77
[30] Obeid M, Tesniere A, Ghiringhelli F, Fimia G M, Apetoh L, Perfettini J L, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Nat. Med., 2007, 13: 54—61
[31] Senzer N N, Kaufman H L, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis J J. J. Clin. Oncol., 2009, 27: 5763—5771
[32] Beatty G L, Chiorean E G, Fishman M P, Saboury B, Teitelbaum U R, Sun W, Huhn R D, Song W, Li D, Sharp L L, Torigian D A, O'Dwyer P J, Vonderheide R H. Science, 2011, 331: 1612—1616
[33] Schreiber R D, Old L J, Smyth M J. Science, 2011, 331: 1565—1570

[1] Shunxin Gu, Qin Jiang, Pengfei Shi. Antitumor Activity and Application of Luminescent Iridium(Ⅲ) Complexes [J]. Progress in Chemistry, 2022, 34(9): 1957-1971.
[2] Haidi Feng, Lu Zhao, Yunfeng Bai, Feng Feng. The Application of Nanoscale Metal-Organic Frameworks for Tumor Targeted Therapy [J]. Progress in Chemistry, 2022, 34(8): 1863-1878.
[3] Xiaofeng Chen, Kaiyuan Wang, Fangming Liang, Ruiqi Jiang, Jin Sun. Exosomes Drug Delivery Systems and Their Application in Tumor Treatment [J]. Progress in Chemistry, 2022, 34(4): 773-786.
[4] Jiali Wang, Ling Zhu, Chen Wang, Shengbin Lei, Yanlian Yang. Nanotechnology for Detection of Circulating Tumor Cells and Extracellular Vesicles [J]. Progress in Chemistry, 2022, 34(1): 178-197.
[5] Xiaodong Jing, Ying Sun, Bing Yu, Youqing Shen, Hao Hu, Hailin Cong. Rational Design of Tumor Microenvironment Responsive Drug Delivery Systems [J]. Progress in Chemistry, 2021, 33(6): 926-941.
[6] Huifeng Xu, Yongqiang Dong, Xi Zhu, Lishuang Yu. Novel Two-Dimensional MXene for Biomedical Applications [J]. Progress in Chemistry, 2021, 33(5): 752-766.
[7] Jiawei Liu, Jing Wang, Qi Wang, Quli Fan, Wei Huang. Applications of Activatable Organic Photoacoustic Contrast Agents [J]. Progress in Chemistry, 2021, 33(2): 216-231.
[8] Xinyu Wang, Fuping Zhao, Ru Zhang, Ziru Sun, Shengnan Liu, Qingzhi Gao. Development of Hypoxia Inducible Factor-1 Small Molecule Inhibitors as Antitumor Agents [J]. Progress in Chemistry, 2021, 33(12): 2259-2269.
[9] Qixiao Guan, Heze Guo, Hongjing Dou. Nanocarriers Modified by Cell Membrane and Their Applications in Tumor Immunotherapy [J]. Progress in Chemistry, 2021, 33(10): 1823-1840.
[10] Shan Guo, Xiang Zhou. Detection of Circulating Tumor Cell in Vivo:Technology and Application [J]. Progress in Chemistry, 2021, 33(1): 1-12.
[11] Qing Wu, Yiyuan Tang, Miao Yu, Yueying Zhang, Xingmei Li. Stimuli-Responsive DNA Nanostructure Drug Delivery System Based on Tumor Microenvironment [J]. Progress in Chemistry, 2020, 32(7): 927-934.
[12] Zi-Yue Xu, Yun-Chang Zhang, Jia-Le Lin, Hui Wang, Dan-Wei Zhang, Zhan-Ting Li. Supramolecular Self-Assembly Applied for the Design of Drug Delivery Systems [J]. Progress in Chemistry, 2019, 31(11): 1540-1549.
[13] Zhaoxuan Fan, Liang Zhao, Xueji Zhang. The Detection of Circulating Tumor DNA: From Digitalization to Sequencing [J]. Progress in Chemistry, 2019, 31(10): 1384-1395.
[14] Xiaowei Cao, Shuai Chen, Min Bao, Hongcan Shi, Wei Li. Synthesis and Surface Modifications of Au Nanostars and Their Applications in Biomedical Fields [J]. Progress in Chemistry, 2018, 30(9): 1380-1391.
[15] Xiaoxiao Tan, Guoshuai Li, Qingpeng Wang, Bingquan Wang, Dacheng Li, Peng George Wang. Small Molecular Platinum(Ⅳ) Compounds as Antitumor Agents [J]. Progress in Chemistry, 2018, 30(6): 831-846.
Viewed
Full text


Abstract

Research Progress of Anti-Cancer Vaccine